International experience with tenoxicam: a review.
For new drugs with relatively few side-effects, a large side-effect database needs to be gathered before a realistic appraisal of a drug's side-effects profile can be made. The database can be collected in different ways. A United Kingdom database of 4,125 patients receiving tenoxicam and 1,132 patients receiving comparator drugs requires all events, even if only remotely related to therapy, to be reported. An international database, currently numbering 5,537 patients receiving tenoxicam and 2,948 patients receiving comparator non-steroidal anti-inflammatory drugs (NSAIDs), is less stringent; only events felt by the physician to be directly related to the drug are reported. Both these databases are open. A separate randomised, double-blind, UK study compared 657 patients on tenoxicam 20 mg/day and 663 patients on piroxicam 20 mg/day. All three methods of data collection show a similar trend which is that tenoxicam causes fewer serious gastrointestinal side-effects than piroxicam, although where homogeneity of population allows the application of statistics, this does not achieve statistical significance. In all other respects the side-effects profile of tenoxicam was virtually identical to that seen with piroxicam and similar to that seen with other NSAIDs.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007256:Information Systems; D007391:International Cooperation; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006113:United Kingdom
D010894:Piroxicam; C032801:tenoxicam